Project Grant R01HL180768
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...
- This $802,762 federal Project Grant was awarded on February 1, 2025 by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The University of Texas Southwestern Medical Center in Dallas, TX. The grant supports research to interpret the impact of genetic variants, both coding and non-coding, on the development of congenital heart disease (CHD) by defining cardiac gene regulatory networks. The research aims to characterize the functions of variants in...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $126,306 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Washington. The goal of this 2-year award is to establish a system to accelerate the reclassification of variants of unknown significance in the MYH7 gene, which cause hypertrophic cardiomyopathy, and determine the role of genetic modifiers that influence the severity of this disease. The research will utilize human induced pluripotent...
- The University of Maryland, Baltimore received a $678,445 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to study a novel regulator of cardiomyocyte function and homeostasis. The research aims to determine the mechanisms by which the C5ORF51 (C5X) protein modulates transcription in cardiomyocytes and investigate its role in adult cardiomyocyte proliferation and maturation. This innovative research has the potential to uncover...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $487,567 to Indiana University to conduct integrative genomic analysis and develop high-dimensional risk prediction models for congenital heart defects (CHDs). The research aims to identify genetic variants and biological pathways associated with CHDs, as well as build predictive models leveraging genetic, epigenetic,...
- This Project Grant award, valued at $1,088,500.00, was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The University of Iowa. The award supports three independent research projects related to genetic and molecular mechanisms of heart disease. Project #1 aims to define microRNA (miR) targeting events and their biological relevance in the heart, as well as understand the clinical significance of single nucleotide polymorphisms (SNPs)...
- This Project Grant award of $706,519 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the regulatory role of the NIPBL gene in human cardiac cells. The grant recipient, the University of Pittsburgh, is using an inducible NIPBL depletion human induced pluripotent stem cell model to study NIPBL's function as a transcription regulator in cardiomyocytes. The research aims to elucidate the mechanisms by which NIPBL...
- This federal Project Grant award of $680,583.00 from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research to discover genetic modifiers and novel therapies for anthracycline-induced cardiotoxicity. The study aims to use zebrafish models to test candidate genes identified from human genome-wide association studies, as well as explore the role of aging-associated epicardial remodeling in cardiotoxicity. Key areas of focus include...
- This federal Project Grant award, valued at $125,983 and running from August 1, 2025 through May 31, 2027, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research at Duke University to identify novel and conserved regulators of cardiomyocyte polyploidy, which is crucial for proper heart function. The project aims to utilize Drosophila genetics, imaging, and mammalian cardiomyocyte models...
- This $161,500 Project Grant was awarded by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The grant is intended to establish basic science-clinical collaborations to understand the molecular mechanisms of heterotaxy, a severe form of congenital heart disease that affects 3-4% of patients with congenital heart defects. The funding will support research at the University of Virginia to...
This federal Project Grant award of $777,016.00 from the National Heart Lung and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) supports research to functionally characterize genes and genetic variants associated with hypoplastic heart syndrome (HHS) in the Drosophila model organism. The University of Maryland, Baltimore is the primary awardee and will apply a high-throughput "gene replacement" approach to validate 386 genetic variants linked to HHS, categorized as loss-of-function, gain-of-function, and variants of uncertain effect. The project aims to confirm the causal relationship between these variants and HHS, as well as investigate polygenic interactions in 18 patients carrying multiple high-confidence variants. The research will establish an efficient platform for variant screening and validation to advance understanding of the genetic basis of HHS and inform potential gene therapy approaches. The award period runs from Aug 1, 2025 to May 31, 2029.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $777.0k | 7/31/25 |